Method Uses Monoterpene or Sesquiterpene to Permeabilize Blood Brain Barrier

ChangeBridge: Patent Apps - Pharma (A61K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published a patent application detailing a method for permeabilizing the blood-brain barrier using monoterpenes or sesquiterpenes. The application, assigned to the University of Southern California, describes a treatment for central nervous system cancers involving perillyl alcohol and CAR-T cells.

View original document View source feed page

What changed

This document is a published patent application (US20260083685A1) from the USPTO, detailing a novel method for permeabilizing the blood-brain barrier. The invention, assigned to the University of Southern California, utilizes monoterpenes or sesquiterpenes, specifically perillyl alcohol (POH), in conjunction with chimeric antigen receptor T-cells (CAR-T cells) for the treatment of central nervous system cancers such as malignant gliomas and metastatic brain tumors. The application suggests intraarterial injection as a potential administration route.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in pharmaceutical treatments for CNS cancers. Companies involved in oncology drug development, CAR-T cell therapy, or blood-brain barrier penetration technologies should monitor this and related patent filings for insights into emerging therapeutic approaches and potential intellectual property landscapes.

Source document (simplified)

← USPTO Patent Applications

METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER

Application US20260083685A1 Kind: A1 Mar 26, 2026

Assignee

UNIVERSITY OF SOUTHERN CALIFORNIA

Inventors

Thomas Chen

Abstract

The present invention relates to using monoterpene or sesquiterpene to permeabilize the blood brain barrier. The present invention relates to a method of treating a central nervous system (CNS) cancer wherein perillyl alcohol (POH) is administered to a mammal before or concurrently with a therapeutic agent that is a chimeric antigen receptor T-cell (CAR-T cell). The POH and CAR-T cells can be administered by intraarterial injection. The CNS cancer can be a malignant glioma, pilocytic astrocytomas (grade I), meningiomas, metastatic brain tumors, or pituitary adenomas.

CPC Classifications

A61K 31/045 A61K 9/0019 A61K 9/0043 A61K 9/0078 A61K 9/0085 A61K 31/4015 A61K 31/415 A61K 31/4188 A61K 31/4745 A61K 39/3955 A61K 40/11 A61K 40/31 A61K 40/4211 A61K 45/06 A61P 35/00 C07K 14/70503 C07K 16/2809 C07K 16/42 C12N 5/0638 A61K 2039/505 A61K 2039/54 A61K 2039/543 A61K 2039/544 A61K 2039/545 A61K 2239/31 A61K 2239/38 A61K 2239/48 C07K 2317/52 C12N 5/16 C12P 5/007